Zacks: Analysts Expect 10x Genomics, Inc. (NASDAQ:TXG) to Announce -$0.25 Earnings Per Share


Share on StockTwits

Equities analysts predict that 10x Genomics, Inc. (NASDAQ:TXG) will report earnings of ($0.25) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for 10x Genomics’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.15). 10x Genomics reported earnings per share of ($0.22) during the same quarter last year, which suggests a negative year over year growth rate of 13.6%. The firm is expected to announce its next earnings results on Monday, May 10th.

On average, analysts expect that 10x Genomics will report full-year earnings of ($0.75) per share for the current fiscal year, with EPS estimates ranging from ($0.90) to ($0.57). For the next year, analysts anticipate that the firm will report earnings of ($0.13) per share, with EPS estimates ranging from ($0.49) to $0.21. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover 10x Genomics.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Tuesday, February 16th. The company reported ($3.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($3.59). 10x Genomics had a negative return on equity of 19.98% and a negative net margin of 51.27%. The company had revenue of $112.22 million for the quarter, compared to analyst estimates of $101.20 million.

A number of research analysts have recently weighed in on TXG shares. Citigroup raised their price objective on shares of 10x Genomics from $195.00 to $240.00 and gave the stock a “buy” rating in a research note on Thursday, February 25th. Morgan Stanley boosted their target price on shares of 10x Genomics from $145.00 to $215.00 and gave the stock an “overweight” rating in a research report on Thursday, February 25th. Cowen boosted their target price on shares of 10x Genomics from $155.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, February 25th. Zacks Investment Research raised shares of 10x Genomics from a “sell” rating to a “hold” rating in a research note on Thursday, March 25th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their target price on shares of 10x Genomics from $165.00 to $195.00 in a research note on Wednesday, December 16th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $183.70.

In other 10x Genomics news, insider Benjamin J. Hindson sold 33,750 shares of the firm’s stock in a transaction that occurred on Monday, February 1st. The shares were sold at an average price of $175.98, for a total transaction of $5,939,325.00. Following the sale, the insider now directly owns 69,686 shares in the company, valued at approximately $12,263,342.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Serge Saxonov sold 10,000 shares of 10x Genomics stock in a transaction that occurred on Monday, February 1st. The shares were sold at an average price of $176.00, for a total transaction of $1,760,000.00. Following the completion of the sale, the chief executive officer now owns 889,576 shares in the company, valued at $156,565,376. The disclosure for this sale can be found here. Insiders have sold a total of 144,416 shares of company stock worth $25,731,264 in the last three months. 13.28% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of TXG. Advisory Services Network LLC acquired a new position in 10x Genomics during the fourth quarter worth $30,000. HM Payson & Co. acquired a new position in 10x Genomics during the third quarter worth $27,000. Lazard Asset Management LLC acquired a new position in 10x Genomics during the fourth quarter worth $44,000. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. bought a new position in 10x Genomics during the fourth quarter worth $96,000. Finally, Black Swift Group LLC bought a new position in 10x Genomics during the fourth quarter worth $142,000. Institutional investors own 68.84% of the company’s stock.

NASDAQ:TXG opened at $185.34 on Thursday. 10x Genomics has a 12 month low of $59.36 and a 12 month high of $201.70. The firm has a market capitalization of $20.16 billion, a PE ratio of -137.29 and a beta of 1.39. The business’s fifty day moving average price is $174.12 and its 200 day moving average price is $158.90.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products.

See Also: CBOE Russell 2000® Volatility Index

Get a free copy of the Zacks research report on 10x Genomics (TXG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.